Argus Research Initiates Coverage On Novo Nordisk with Buy Rating, Announces Price Target of $110
Portfolio Pulse from Benzinga Newsdesk
Argus Research has initiated coverage on Novo Nordisk (NYSE:NVO) with a Buy rating and a price target of $110.
October 02, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk has been given a Buy rating by Argus Research with a price target of $110.
The Buy rating and price target of $110 announced by Argus Research for Novo Nordisk indicates a positive outlook for the company. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100